Anthem Biosciences Soars Out of the Gate: Why the Share Price Is Getting Everyone's Attention 🚀
Hey everyone! I’ve got to tell you all about this crazy cool thing that just happened with Anthem Biosciences. If you’ve never heard of it, buckle up—because this biotech company just made a super impressive splash on the stock market, and it’s like the best kind of plot twist ever. I’ll explain everything in a fun, simple way, just like I’m telling my friends over snacks.
1. What Happened? The IPO Launch!
So, Anthem Biosciences is a big player in something called CRDMO—(that’s “Contract Research, Development & Manufacturing Organization,” but don’t worry about remembering that). Basically, they help create and produce drugs for the world. They went public with an IPO (Initial Public Offering) from July 14 to 16, 2025, priced between ₹540 and ₹570 per share ChittorgarhMoney Sukh+3The Economic Times+3Bitrue+3.
And guess what? People LOVED it. The IPO was oversubscribed 67 times—like, if there were 100 shares, 6,700 people wanted in! Big investors called QIBs piled in too, almost 193 times more demand Bitrue.
2. The Big Debut: Listing Day Madness
On July 21, 2025, Anthem’s shares hit the markets — and it was wild!
-
It opened at ₹723.05 on NSE (National Stock Exchange), 26.85% above the ₹570 IPO price The Economic Times.
-
On BSE, it was ₹723.10, basically the same jump The Economic Times.
-
Technically, that’s a 27% premium—people literally cheered when they saw that number MoneycontrolIndia Today.
-
Then later, it climbed even higher — like to ₹746.70 intraday, giving early investors a sweet ~31% gain The Economic Times.
It’s like if you bought a ₹100 candy bar and it instantly became worth ₹130 — that kind of surprise and excitement!
3. Why Did It Shoot Up?
Lots of reasons! Let me break 'em down:
A) Strong Fundamentals
-
Anthem makes both chemical and biological drugs—super versatile Investing.com Canada+8The Economic Times+8The Economic Times+8.
-
In FY25, they grew revenue by 30% (₹1,930 crore) and net profit up 23% (₹451 crore) The Economic Times+1Bitrue+1.
-
EBITDA margins were a strong ~37%, and debt was low — so they aren’t just fast, they’re smart with money The Economic Times.
B) Large Global Capacity
-
They have India’s largest fermentation capacity at 182 kL — that’s like being the tallest kid in class The Economic Times+1Bitrue+1.
-
They work with over 675 clients across 44 countries — so it’s not just hype; they’ve got serious international trust GoodreturnsBitrue.
C) IPO Mechanics
-
Their IPO was an Offer For Sale (OFS) only, meaning no new shares — just selling old ones. That avoids diluting share value The Economic Times.
-
Big funds like Abu Dhabi Investment Authority, HDFC MF, ICICI Pru, and Quant all invested before — and that’s like having superstars on your team Bitrue.
D) Grey Market Signals
-
In the grey market, whispers of ₹144–154 premium (a listing bump of 25–27%) showed just how hyped everyone was Bitrue+1The Economic Times+1.
4. How Are the Experts Reacting?
Here’s the breakdown:
-
Mahesh Ojha from Hensex said short-term traders should take partial profits (because a 20–25% gain is big!). Long-term fans should watch if fundamentals hold up mintmint.
-
Prashanth Tapse at Mehta Equities gave a "Hold" rating. He thinks a rise to ₹900 is possible soon, and longer term ₹1,000+ The Economic Times.
-
Shivani Nyati from Swastika recommends locking in some profits and using a stop-loss near ₹650 if you hold on The Economic Times.
-
Naren Agarwal says it’s solid—good revenues, no dilution, and strong growth. He thinks it could become a biotech superstar MoneycontrolThe Times of India.
-
Narendra Solanki at Anand Rathi notes it’s priced at a P/E of ~70x (based on FY25), which is fair given margins and growth. He says long-term investors can hold MoneycontrolThe Times of India.
-
ET's Nishtha Awasthi adds it's a “hold”—with ₹900 as near target and ₹1,000 for longer goals The Economic Times.
5. Share Price Buzz
-
Right now, Anthem is trading around ₹730–735, up ~28% in just one day The Economic Times.
-
Intraday it even hit ₹746.70 on BSE, giving some lucky early buyers 31% gains The Economic Times+1Anthem Biosciences+1.
6. What Should You Do?
So what’s that mean for you if you’re thinking about buying?
Short term?
-
Some say take partial profits now — not a bad idea after a 25–30% jump mintMoneycontrol.
Long term?
-
If you believe in Anthem’s strategy, technology, and global demand, experts are saying hold for ₹900 soon, maybe ₹1,000+ later mintMoneycontrol.
-
But if you missed the IPO, maybe wait for a dip to ₹650–680, then buy in slowly The Economic Times.
What to watch:
-
Do they keep growing revenue and profit?
-
Can they expand capacity like they plan?
-
Will competitors eat into margins?
-
Any news on global client wins or new drug projects?
7. What Makes Anthem Cool?
-
First-mover edge: Huge fermentation setup + global biotech focus.
-
Profitable growth: Nearly ₹2,000 crore revenue and strong margins (~37%!) The Economic TimesBitrue.
-
No dilution: OFS only = clean share count.
-
Big names backing it: International funds bought in before IPO The Economic Times+2Anthem Biosciences+2The Economic Times+2.
-
Sector tailwinds: Pharma outsourcing to India is still a big trend.
8. In Simple Kid-Speak…
Imagine you bought a toy for ₹100, and the next day it’s worth ₹130, and people are saying it might go to ₹150, and there's a rumor it could hit ₹170 later. That’s basically what happened here, but with shares!
9. The TL;DR
| Category | Details |
|---|---|
| IPO Price | ₹570 (mid-point of ₹540–570) Money Sukh+2Chittorgarh+2Bitrue+2 |
| Listing Price | ~₹723 (up ~27%) mintMoneycontrol |
| Intraday High | ₹746.70 (~31% gain) The Times of IndiaThe Economic Times |
| Current Price | ~₹730–735 (up ~28%) mintupstox.com |
| Expert View | Hold, with ₹900 short-term & ₹1,000 long-term mintThe Times of India |
| Buy Levels | Best to buy near ₹650–680 if missed IPO mintThe Economic Times |
🧠Final Thoughts
Anthem Biosciences just aced its debut. It has awesome growth, big muscle in biotech manufacturing, no share dilution, and serious investor support. That’s textbook "awesome startup" meets "big-league investor."
If you’re playing short term, think about locking in some profits. If you're in for the long haul—be ready for volatility, but fundamentals say it's a solid pick. Just don't buy at the top if it’s already zoomed too much!
Let me know if you want another breakdown—like a “top 5 things to watch” list or even a fun comic-style recap. I’ve totally got you covered!
Related Query's :-
anthem biosciences share price
anthem biosciences ipo listing
anthem biosciences ipo gmp share price
anthem biosciences
anthem biosciences ipo
anthem share price
nse
anthem biosciences share price target 2025
anthem biosciences ipo gmp
bse
nse india
anthem biosciences ipo gmp today
anthem biosciences share
anthem
anthem biosciences ipo listing price
ipo listing time
anthem biosciences listing price
anthem biosciences ipo listing date
anthem biosciences listing time
anthem biosciences ltd
anthem biosciences ipo listing time
anthem biosciences listing
0 Comments